Breast Cancer Drug Tamoxifen Binds to Cannabinoid Receptors, Opening Door for New Drug Development
Different forms of the breast cancer drug tamoxifen and its metabolites bind to cannabinoid receptors with varying selectivity, suggesting this drug's chemical structure could serve as a blueprint for developing new cannabinoid-based medicines.
Quick Facts
What This Study Found
Tamoxifen is primarily known as a breast cancer drug, but this study revealed that its chemical structure interacts with cannabinoid receptors in ways that could be therapeutically useful.
The researchers tested tamoxifen's two mirror-image forms (isomers) and their metabolic breakdown products at both CB1 and CB2 cannabinoid receptors. They found that different forms showed different receptor preferences. One metabolite (Z-4OHT) had notably higher affinity for both receptor types, while another (endoxifen) was relatively CB1-selective.
All tested forms acted as inverse agonists at both CB1 and CB2 receptors, meaning they reduce the baseline activity of these receptors. One form (Z-tamoxifen) was more potent than a well-known reference compound (AM630) at CB2 receptors.
Key Numbers
Z-4OHT showed higher affinity for both CB1 and CB2 receptors compared to E-isomers. Endoxifen isomers were relatively CB1-selective. Z-tamoxifen exceeded the efficacy of the full inverse agonist AM630 at CB2 receptors. Z-tamoxifen and Z-endoxifen showed insurmountable antagonism at CB1 and CB2 receptors respectively.
How They Did This
Laboratory study using cell-based assays to measure binding affinity, G-protein activation, and effects on adenylyl cyclase signaling at human CB1 and CB2 cannabinoid receptors. Different isomers and metabolites of tamoxifen were systematically compared.
Why This Research Matters
This research opens a new avenue for cannabinoid drug development. Rather than starting from scratch, medicinal chemists could use tamoxifen's chemical scaffold as a starting point to design drugs that precisely target cannabinoid receptors, potentially avoiding the psychoactive effects of THC while harnessing therapeutic benefits.
The Bigger Picture
The discovery that existing FDA-approved drug structures interact with cannabinoid receptors could accelerate drug development. This approach of repurposing known chemical scaffolds has successfully produced new medicines in other therapeutic areas.
What This Study Doesn't Tell Us
All experiments were conducted in cell cultures, not in living organisms. The concentrations needed for cannabinoid receptor effects may differ from those achieved during normal tamoxifen therapy. The therapeutic relevance of these interactions remains to be tested in animal models.
Questions This Raises
- ?Do patients taking tamoxifen for breast cancer experience any effects mediated through cannabinoid receptors?
- ?Could tamoxifen-derived compounds be designed to selectively target one cannabinoid receptor type?
Trust & Context
- Key Stat:
- Tamoxifen scaffold binds to both CB1 and CB2 receptors with isomer-specific selectivity
- Evidence Grade:
- Cell-based laboratory study demonstrating receptor binding and functional activity. No in vivo data yet.
- Study Age:
- Published in 2016. This line of research represents early-stage drug discovery that typically takes years to translate to clinical applications.
- Original Title:
- Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
- Published In:
- PloS one, 11(12), e0167240 (2016)
- Authors:
- Ford, Benjamin M(2), Franks, Lirit N(2), Radominska-Pandya, Anna, Prather, Paul L
- Database ID:
- RTHC-01156
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why is a breast cancer drug relevant to cannabinoid research?
Tamoxifen's chemical structure happens to interact with cannabinoid receptors. This means its molecular framework could be used as a starting point to develop entirely new cannabinoid-targeting drugs.
Could this lead to new medicines?
Potentially. The different receptor selectivity shown by different tamoxifen forms gives chemists multiple starting points for designing drugs that target specific cannabinoid receptors for different therapeutic purposes.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01156APA
Ford, Benjamin M; Franks, Lirit N; Radominska-Pandya, Anna; Prather, Paul L. (2016). Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.. PloS one, 11(12), e0167240. https://doi.org/10.1371/journal.pone.0167240
MLA
Ford, Benjamin M, et al. "Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.." PloS one, 2016. https://doi.org/10.1371/journal.pone.0167240
RethinkTHC
RethinkTHC Research Database. "Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity ..." RTHC-01156. Retrieved from https://rethinkthc.com/research/ford-2016-tamoxifen-isomers-and-metabolites
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.